Immunoprecise Antibodies Ltd reports results for the quarter ended in July - Earnings Summary

Mindwalk Holdings

14/09/2023 14:31

* Immunoprecise Antibodies Ltd  IPA.OQ  reported a quarterly
adjusted loss of 14 cents​​ per share for the quarter ended in
July. The mean expectation of two analysts for the quarter was
for a loss of 20 cents per share.
    * Revenue rose 21.3% to C$5.69 million from a year ago;
analysts
expected C$5.35 million. 
    * Immunoprecise Antibodies Ltd's reported EPS for the
quarter was
a loss of 14 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Immunoprecise Antibodies Ltd shares had fallen by 31.8%
this
quarter and lost 61.2% so far this year.
    * The company reported a quarterly loss of C$3.57 million.
    * Wall Street's median 12-month price target for
Immunoprecise
Antibodies Ltd is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
September 14 at 01:31 p.m. UTC. ​All figures in Canadian dollars
unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jul. 31 2023      -0.20          -0.14          Beat
 Apr. 30 2023      -0.17          -0.21          Missed
 Jan. 31 2023      -0.23          -0.19          Beat
 Oct. 31 2022      -0.19          -0.30          Missed